Daiichi Sankyo has said that there are procedural delays in completing the open offer for acquiring an additional 20% equity of Ranbaxy. The delay pertains to payments to shareholders who have subscribed to the Japanese company's open offer for acquiring an additional 20% equity of Ranbaxy.